Overview

Study of Tacrolimus vs Mycophenolate Mofetil in Pediatric Patients With Nephrotic Syndrome

Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Primary nephrotic syndrome accounts for approximately 90% of the total number of nephrotic syndrome in childhood and it is the most common glomerular disease in children. Although treatment with steroids is uesful for primary nephrotic syndrome, proning to cause frequent relapse/steroid-dependent nephrotic syndrome after treatment, and the usage of immunosuppressive agents has become a new choice for the treatment of such patients. This study is a prospective, randomized, multicenter, open, parallel controlled trial, evaluating the efficacy and safety of steroid combined with the immunosuppressive agents which are tacrolimus and mycophenolate mofetil to children who with frequently relapsing or steroid-dependent nephrotic syndrome, all we wish to obtain the proper drug choice and individualized treatment options for children with nephrotic syndrome.
Phase:
Phase 4
Details
Lead Sponsor:
The Children's Hospital of Zhejiang University School of Medicine
Collaborators:
Chengdu Women and Children's Center Hospital
Children's Hospital of Fudan University
First Affiliated Hospital of Zhongshan Medical University
Nanjing Children's Hospital
Peking University First Hospital
Second Xiangya Hospital of Central South University
Tongji Hospital
Treatments:
Mycophenolic Acid
Tacrolimus